Clinical Trial Update: Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating birinapant in combination with intensity-modulated re-irradiation therapy for locally recurrent head and neck squamous cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Nasopharyngeal Squamous Cell Carcinoma
• Sinonasal Squamous Cell Carcinoma

Drugs mentioned

• Birinapant

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-23